The median age of patients was 58 years (interquartile range [IQR], 49 to 68 years), and 60.3% of the patients were men. The median interval time between symptom onset and randomization was 13 days (IQR, 11 to 16 days). There were no important between-group differences in demographic characteristics, baseline laboratory test results, distribution of ordinal scale scores, or National Early Warning Score 2 (NEWS2) scores at enrollment. During the trial, systemic glucocorticoids were administered in 33.0% of the patients in the lopinavir–ritonavir group and in 35.7% of those in the standard-care group.